FRANKLIN, Tenn. / Apr 15, 2025 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have entered into a definitive agreement to sell their collective 80% ownership interest in Cedar Park Regional Medical Center and certain ancillary businesses located in Cedar Park, Texas, to subsidiaries of Ascension Health for $460 million in cash, subject to certain net working capital and other adjustments. Ascension Health currently holds a minority ownership interest in Cedar Park Regional Medical Center and will purchase the remaining interest through this transaction.
The transaction is expected to close late in the second quarter or early in the third quarter of 2025, subject to regulatory approvals and closing conditions.
This transaction is among the additional potential divestitures discussed on the Company’s fourth quarter and end of year 2024 earnings call and in subsequent public appearances.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. The Company’s subsidiaries own or lease 72 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
Last Trade: | US$2.83 |
Daily Change: | 0.07 2.54 |
Daily Volume: | 2,620,505 |
Market Cap: | US$393.230M |
February 18, 2025 December 11, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load